Current and future therapies for treating chronic spontaneous urticaria

Area of Science:

• Urticaria research
• Dermatology
• Immunology

Background:

• Chronic spontaneous urticaria (CSU) significantly impairs patients' quality of life.
• Current management guidelines recommend a stepwise treatment approach.

Purpose of the Study:

• To review the established and emerging treatment options for chronic spontaneous urticaria (CSU).
• To evaluate the efficacy and evidence base for various CSU therapies.

Main Methods:

• Analysis of international guidelines (EAACI/GA(2)LEN/EDF/WAO) for CSU management.
• Review of first-line (H1-antihistamines), second-line (up-dosing), and refractory treatments (omalizumab, ciclosporin A, montelukast).
• Consideration of short-term corticosteroid use and emerging therapeutic targets.

Main Results:

• Second-generation H1-antihistamines and omalizumab are the only licensed treatments within the guideline algorithm.
• Omalizumab demonstrates a rapid and significant symptomatic effect in CSU patients.
• Evidence for alternative treatments is generally of low quality.

Conclusions:

• Optimal long-term omalizumab regimens require further investigation.
• The efficacy of alternative CSU treatments needs more robust study.
• Key research areas include the potential for remission induction, response predictors, prognostic factors, and underlying pathomechanisms of CSU.